Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.14.5 extracted from

  • Tsai, T.Y.; Hsu, T.; Chen, C.T.; Cheng, J.H.; Yeh, T.K.; Chen, X.; Huang, C.Y.; Chang, C.N.; Yeh, K.C.; Hsieh, S.H.; Chien, C.H.; Chang, Y.W.; Huang, C.H.; Huang, Y.W.; Huang, C.L.; Wu, S.H.; Wang, M.H.; Lu, C.T.; Chao, Y.S.; Jiaang, W.T.
    Novel trans-2-aryl-cyclopropylamine analogues as potent and selective dipeptidyl peptidase IV inhibitors (2009), Bioorg. Med. Chem., 17, 2388-2399.
    View publication on PubMed
Search for more literature for 3.4.14.5

Inhibitors

Inhibitors Comment Organism Structure
3-([2-[(2S)-2-cyano-4,4-difluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1S,2R)-2-(3-chlorophenyl)cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1R,2S)-2-(3-chlorophenyl)cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1S,2R)-2-(3-chlorophenyl)cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[2-[3-(trifluoromethyl)phenyl]cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[2-[4-(trifluoromethyl)phenyl]cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(2,4-di-fluorophenyl)cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(3,4-di-chlorophenyl)cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(3,4-di-fluorophenyl)cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(3,4-di-methoxyphenyl)cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(3,5-di-fluorophenyl)cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(3-chlorophenyl)cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(3-fluorophenyl)cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(3-trifluoromethoxyphenyl)cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(4-chlorophenyl)cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(4-fluorophenyl)cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-phenylcyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]-amino)-3-methyl-N-[trans-2-(4-methyl-1,3-thiazol-5-yl)cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1R,2S)-2-(3-chlorophenyl)cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1S,2R)-2-(3-chlorophenyl)cyclopropyl]butanamide 15 nM DPP-IV inhibitor with high selectivity over DPP-II, DPP8 and FAP Rattus norvegicus
3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1S,2R)-2-(3-ethoxyphenyl)cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1S,2R)-2-(3-fluorophenyl)cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1S,2R)-2-(3-methoxyphenyl)cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1S,2R)-2-(3-trifluoromethoxyphenyl)cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1S,2R)-2-(4-methoxyphenyl)cyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1S,2R)-2-phenylcyclopropyl]butanamide
-
 Rattus norvegicus
3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(pyridin-3-yl)cyclopropyl]butanamide
-
 Rattus norvegicus
sitagliptin MK-0431 Rattus norvegicus
vildagliptin LAF237 Rattus norvegicus

Organism

Organism UniProt Comment Textmining
Rattus norvegicus
-
-
-

Source Tissue

Source Tissue Comment Organism Textmining
blood plasma
-
 Rattus norvegicus
-

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
Gly-L-Pro-7-amido-4-methylcoumarin + H2O
-
 Rattus norvegicus Gly-L-Pro + 7-amino-4-methylcoumarin
-
 ?

Synonyms

Synonyms Comment Organism
CD26
-
 Rattus norvegicus
dipeptidyl peptidase IV
-
 Rattus norvegicus
DPP-IV
-
 Rattus norvegicus

IC50 Value

IC50 Value IC50 Value Maximum Comment Organism Inhibitor Structure
0.000015
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1S,2R)-2-(3-chlorophenyl)cyclopropyl]butanamide
0.000016
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]-amino)-3-methyl-N-[trans-2-(4-methyl-1,3-thiazol-5-yl)cyclopropyl]butanamide
0.000017
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1S,2R)-2-(3-ethoxyphenyl)cyclopropyl]butanamide
0.000019
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1S,2R)-2-phenylcyclopropyl]butanamide
0.00002
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1S,2R)-2-(3-trifluoromethoxyphenyl)cyclopropyl]butanamide
0.000021
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1S,2R)-2-(3-fluorophenyl)cyclopropyl]butanamide
0.000022
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1S,2R)-2-(4-methoxyphenyl)cyclopropyl]butanamide
0.000024
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(pyridin-3-yl)cyclopropyl]butanamide
0.000026
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1S,2R)-2-(3-methoxyphenyl)cyclopropyl]butanamide
0.000026
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S)-2-cyano-4,4-difluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1S,2R)-2-(3-chlorophenyl)cyclopropyl]butanamide
0.000027
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S,4S)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1R,2S)-2-(3-chlorophenyl)cyclopropyl]butanamide
0.00003
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus sitagliptin
0.000042
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(3-chlorophenyl)cyclopropyl]butanamide
0.000047
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1S,2R)-2-(3-chlorophenyl)cyclopropyl]butanamide
0.000051
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus vildagliptin
0.000054
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(4-fluorophenyl)cyclopropyl]butanamide
0.000056
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[(1R,2S)-2-(3-chlorophenyl)cyclopropyl]butanamide
0.00006
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[2-[3-(trifluoromethyl)phenyl]cyclopropyl]butanamide
0.000063
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(3,4-di-fluorophenyl)cyclopropyl]butanamide
0.000064
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(3-fluorophenyl)cyclopropyl]butanamide
0.000068
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(3,4-di-chlorophenyl)cyclopropyl]butanamide
0.000073
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(3-trifluoromethoxyphenyl)cyclopropyl]butanamide
0.000075
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(3,5-di-fluorophenyl)cyclopropyl]butanamide
0.000084
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(2,4-di-fluorophenyl)cyclopropyl]butanamide
0.000085
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-phenylcyclopropyl]butanamide
0.000085
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[2-[4-(trifluoromethyl)phenyl]cyclopropyl]butanamide
0.000086
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(4-chlorophenyl)cyclopropyl]butanamide
0.000101
-
 in 25 mM tris(hydroxymethyl)-aminomethane HCl (pH 7.4), 140 mM NaCl, 10 mM KCl, and 0.1% bovine serum albumin Rattus norvegicus 3-([2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino)-3-methyl-N-[trans-2-(3,4-di-methoxyphenyl)cyclopropyl]butanamide